332 related articles for article (PubMed ID: 30293110)
1. Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.
Dorst J; Ludolph AC; Senel M; Tumani H
J Neurol; 2018 Dec; 265(12):2906-2915. PubMed ID: 30293110
[TBL] [Abstract][Full Text] [Related]
2. Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.
Galldiks N; Burghaus L; Dohmen C; Teschner S; Pollok M; Leebmann J; Frischmuth N; Hollinger P; Nazli N; Fassbender C; Klingel R; Benzing T; Fink GR; Haupt WF
Eur Neurol; 2011; 66(4):183-9. PubMed ID: 21912134
[TBL] [Abstract][Full Text] [Related]
3. A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy.
Lieker I; Slowinski T; Harms L; Hahn K; Klehmet J
J Clin Apher; 2017 Dec; 32(6):486-493. PubMed ID: 28485075
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
5. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
7. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy.
Kuwabara S; Isose S; Mori M; Mitsuma S; Sawai S; Beppu M; Sekiguchi Y; Misawa S
J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1054-9. PubMed ID: 25424435
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up.
Jann S; Bramerio MA; Facchetti D; Sterzi R
J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):70-3. PubMed ID: 18768571
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
10. Different types of chronic inflammatory demyelinating polyneuropathy have a different clinical course and response to treatment.
Jann S; Beretta S; Bramerio MA
Muscle Nerve; 2005 Sep; 32(3):351-6. PubMed ID: 16003765
[TBL] [Abstract][Full Text] [Related]
11. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
[TBL] [Abstract][Full Text] [Related]
12. Acute-onset chronic inflammatory demyelinating polyneuropathy: An electrodiagnostic study.
Anadani M; Katirji B
Muscle Nerve; 2015 Nov; 52(5):900-5. PubMed ID: 25809534
[TBL] [Abstract][Full Text] [Related]
13. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
[TBL] [Abstract][Full Text] [Related]
15. Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report.
Jin Y; Chu H; Dong H; Wang H; Wang Q; Zhao X; Qin D; Lu Z; Weng C
BMC Neurol; 2022 Nov; 22(1):400. PubMed ID: 36324078
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy.
Kaplan A; Brannagan TH
Muscle Nerve; 2017 Apr; 55(4):476-482. PubMed ID: 27463215
[TBL] [Abstract][Full Text] [Related]
17. CIDP variants in diabetes: measuring treatment response with a small nerve fiber test.
Névoret ML; Vinik AI
J Diabetes Complications; 2015 Mar; 29(2):313-7. PubMed ID: 25466645
[TBL] [Abstract][Full Text] [Related]
18. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.
Nobile-Orazio E
J Peripher Nerv Syst; 2014 Mar; 19(1):2-13. PubMed ID: 24612201
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammatory demyelinating polyradiculoneuropathy.
Van den Bergh PY; Rajabally YA
Presse Med; 2013 Jun; 42(6 Pt 2):e203-15. PubMed ID: 23623582
[TBL] [Abstract][Full Text] [Related]
20. Motor-dominant chronic inflammatory demyelinating polyneuropathy.
Kimura A; Sakurai T; Koumura A; Yamada M; Hayashi Y; Tanaka Y; Hozumi I; Yoshino H; Yuasa T; Inuzuka T
J Neurol; 2010 Apr; 257(4):621-9. PubMed ID: 20361294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
